ARCHIVES

FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity.

This article is from The Cancer Letter archive.

Vol. 26 No. 35 | September 29, 2000

Download PDF Visit The Full Archive

Related Articles

Phase IIb Trial of CRLX101 Fails Overall Survival Endpoint

March 29, 2013

St. Jude, Washington University Plan $65 Million Pediatric Cancer Genome Project

January 29, 2010

Trial Begins To Test Method To Test For Colorectal Cancer

May 28, 2004

CCIRC Report Suggests Ways To Enhance Role Of Surgeons

July 22, 1977

In Brief: “Massive Reassessment” Of Centers Going On, Tim Talbot Believes; WHO Drops ICRB Service

December 9, 1977

DCBD Board Approved Concepts For New Grants In Cytogenetics Solid Tumor Diagnoses

December 13, 1984